Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness-Reference-Cited by-同舟云学术

Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness

Published:2017-01 Issue:1 Volume:8 Page:156-164
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Author:

Harrington Karra D.¹²,Lim Yen Ying¹³,Ames David⁴⁵,Hassenstab Jason⁶⁷⁸,Laws Simon M.²⁹¹⁰,Martins Ralph N.⁹¹¹,Rainey‐Smith Stephanie⁹¹¹,Robertson Joanne¹,Rowe Christopher C.¹²¹³,Salvado Olivier¹⁴,Doré Vincent¹²¹⁴,Villemagne Victor L.¹¹²¹³,Snyder Peter J.¹⁵¹⁶,Masters Colin L.¹,Maruff Paul¹³,

Affiliation:

1. The Florey Institute, The University of MelbourneParkvilleVictoriaAustralia

2. Cooperative Research Centre for Mental HealthParkvilleVictoriaAustralia

3. CogState Ltd.MelbourneVictoriaAustralia

4. Academic Unit for Psychiatry of Old Age, Department of PsychiatryThe University of MelbourneParkvilleVictoriaAustralia

5. National Ageing Research InstituteParkvilleVictoriaAustralia

6. Charles F. and Joanne Knight Alzheimer's Disease Research CenterWashington University School of MedicineSt. LouisMOUSA

7. Department of NeurologyWashington University School of MedicineSt. LouisMOUSA

8. Department of Psychological & Brain SciencesWashington UniversitySt. LouisMOUSA

9. Centre of Excellence for Alzheimer's Disease Research and CareSchool of Exercise, Biomedical and Health Sciences, Edith Cowan UniversityPerthWestern AustraliaAustralia

10. School of Biomedical SciencesFaculty of Health SciencesCurtin Health Innovation Research Institute, Curtin UniversityWestern AustraliaAustralia

11. Sir James McCusker Alzheimer's Disease Research UnitHollywood Private HospitalPerthWestern AustraliaAustralia

12. Department of Molecular ImagingAustin HealthMelbourneVictoriaAustralia

13. Department of Medicine, Austin HealthThe University of MelbourneMelbourneVictoriaAustralia

14. CSIRO Health and BiosecurityThe Australian eHealth Research CentreBrisbaneQueenslandAustralia

15. Department of NeurologyWarren Alpert School of Medicine, Brown UniversityProvidenceRIUSA

16. Department of NeurologyRhode Island Hospital, Alpert Medical School of Brown UniversityProvidenceRIUSA

Funder

Science and Industry Endowment Fund

Dementia Collaborative Research Centres, Australia

National Health and Medical Research Council

Alzheimer's Association

Alzheimer's Drug Discovery Foundation

Dementia Collaborative Research Centres

McCusker Alzheimer's Research Foundation

Yulgilbar Foundation

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.dadm.2017.05.006

Reference51 articles.

1. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

2. The A4 Study: Stopping AD Before Symptoms Begin?

3. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study

4. Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

5. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in Alzheimer’s disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline;Journal of Pharmacy and Pharmacology;2024-05-20

2. Melatonin reduces β-amyloid accumulation and improves short-term memory in streptozotocin-induced sporadic Alzheimer’s disease model;IBRO Neuroscience Reports;2023-06

3. APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals;EJNMMI Research;2023-03-01

4. Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF Aβ42 moderates the association between insulin resistance and increased CSF tau levels;Neurobiology of Aging;2022-06

5. Altered central and blood glutathione in Alzheimer’s disease and mild cognitive impairment: a meta-analysis;Alzheimer's Research & Therapy;2022-02-05